Growth Metrics

Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2025)

Historic Net Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 135.28%.

  • Iovance Biotherapeutics' Net Margin rose 73900.0% to 135.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 158.79%, marking a year-over-year increase of 2923900.0%. This contributed to the annual value of 226.84% for FY2024, which is 371168100.0% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Net Margin stood at 135.28% for Q3 2025, which was up 73900.0% from 186.27% recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Net Margin high stood at 106.62% for Q4 2024, and its period low was 44750.0% during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Net Margin had a median value of 273.77% in 2025 and averaged 11006.57%.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Net Margin surged by 444379700bps in 2024, and later skyrocketed by 73900bps in 2025.
  • Iovance Biotherapeutics' Net Margin (Quarter) stood at 24140.66% in 2023, then surged by 100bps to 106.62% in 2024, then decreased by -27bps to 135.28% in 2025.
  • Its last three reported values are 135.28% in Q3 2025, 186.27% for Q2 2025, and 235.51% during Q1 2025.